Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.

Inclusion Criteria:

• • At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension)

  • Clinical diagnosis of MASH using:

    • LSM ≥ 8.5kpa And/or
    • FAST score ≥0.67 And/or
    • FibroScan CAP ≥ 275 dB/m And/or
    • FIB-4 > 1.3

Exclusion Criteria:

• • History of drug addiction and alcoholism

  • Cirrhosis or decompensated liver disease
  • Chronic viral hepatitis HBV, HCV)
  • MACE including MI, Stroke, PE etc.
  • Pregnant/lactating women
  • Concurrent use of other investigational drugs
  • History of other liver diseases (viral, autoimmune, drug-induced, alcohol)
  • Previous use of resmetirom in last 6 months
  • Significant renal impairment (eGFR <30)

Its undecided for now will be updated laterwards